These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 26822284)
21. Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin: Fragment-Based Drug Design Facilitated by Dynamic Combinatorial Chemistry. Mondal M; Radeva N; Fanlo-Virgós H; Otto S; Klebe G; Hirsch AK Angew Chem Int Ed Engl; 2016 Aug; 55(32):9422-6. PubMed ID: 27400756 [TBL] [Abstract][Full Text] [Related]
22. Peptide length and leaving-group sterics influence potency of peptide phosphonate protease inhibitors. Brown CM; Ray M; Eroy-Reveles AA; Egea P; Tajon C; Craik CS Chem Biol; 2011 Jan; 18(1):48-57. PubMed ID: 21276938 [TBL] [Abstract][Full Text] [Related]
23. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach. Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998 [TBL] [Abstract][Full Text] [Related]
24. Inhibitors of rhomboid proteases. Wolf EV; Verhelst SH Biochimie; 2016 Mar; 122():38-47. PubMed ID: 26166068 [TBL] [Abstract][Full Text] [Related]
25. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor. Martinez AA; Espinosa BA; Adamek RN; Thomas BA; Chau J; Gonzalez E; Keppetipola N; Salzameda NT Eur J Med Chem; 2018 Sep; 157():1202-1213. PubMed ID: 30193218 [TBL] [Abstract][Full Text] [Related]
26. Investigation of the induced-fit mechanism and catalytic activity of the human cytomegalovirus protease homodimer via molecular dynamics simulations. de Oliveira CA; Guimarães CR; Barreiro G; de Alencastro RB Proteins; 2003 Sep; 52(4):483-91. PubMed ID: 12910449 [TBL] [Abstract][Full Text] [Related]
28. Structure-based optimization of non-peptidic Cathepsin D inhibitors. Grädler U; Czodrowski P; Tsaklakidis C; Klein M; Werkmann D; Lindemann S; Maskos K; Leuthner B Bioorg Med Chem Lett; 2014 Sep; 24(17):4141-50. PubMed ID: 25086681 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 2-{6-[2-(5-phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold. Samanta S; Lim TL; Lam Y ChemMedChem; 2013 Jun; 8(6):994-1001. PubMed ID: 23619931 [TBL] [Abstract][Full Text] [Related]
30. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943 [TBL] [Abstract][Full Text] [Related]
31. Proteases universally recognize beta strands in their active sites. Tyndall JD; Nall T; Fairlie DP Chem Rev; 2005 Mar; 105(3):973-99. PubMed ID: 15755082 [No Abstract] [Full Text] [Related]
32. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. Ekonomiuk D; Su XC; Ozawa K; Bodenreider C; Lim SP; Otting G; Huang D; Caflisch A J Med Chem; 2009 Aug; 52(15):4860-8. PubMed ID: 19572550 [TBL] [Abstract][Full Text] [Related]
33. Process of Fragment-Based Lead Discovery-A Perspective from NMR. Ma R; Wang P; Wu J; Ruan K Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813 [TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. Borthwick AD; Davies DE; Ertl PF; Exall AM; Haley TM; Hart GJ; Jackson DL; Parry NR; Patikis A; Trivedi N; Weingarten GG; Woolven JM J Med Chem; 2003 Oct; 46(21):4428-49. PubMed ID: 14521407 [TBL] [Abstract][Full Text] [Related]
35. Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease. Tong L; Qian C; Massariol MJ; Déziel R; Yoakim C; Lagacé L Nat Struct Biol; 1998 Sep; 5(9):819-26. PubMed ID: 9731777 [TBL] [Abstract][Full Text] [Related]
36. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384 [TBL] [Abstract][Full Text] [Related]
37. Fragment-based discovery of BACE1 inhibitors using functional assays. Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414 [TBL] [Abstract][Full Text] [Related]
38. Latency, thermal stability, and identification of an inhibitory compound of mirolysin, a secretory protease of the human periodontopathogen Zak KM; Bostock MJ; Waligorska I; Thøgersen IB; Enghild JJ; Popowicz GM; Grudnik P; Potempa J; Ksiazek M J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1267-1281. PubMed ID: 34210221 [TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease. Borthwick AD; Weingarten G; Haley TM; Tomaszewski M; Wang W; Hu Z; Bedard J; Jin H; Yuen L; Mansour TS Bioorg Med Chem Lett; 1998 Feb; 8(4):365-70. PubMed ID: 9871686 [TBL] [Abstract][Full Text] [Related]
40. Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease. Batra R; Khayat R; Tong L Nat Struct Biol; 2001 Sep; 8(9):810-7. PubMed ID: 11524687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]